Weight-loss drug demand won't slow down while tech stumbles — buy Eli Lilly's post-guidance strength

Verdict: strong Lilly thesis, but wait for a pullback that hasn't arrived

Our stance is wait over the next three months: the business case is strong, but the entry conditions are far from met and the trade itself has never been measured (historical performance could not be computed because LLY's raw and adjusted price series use different bases, so no robust parameter setup exists). The strongest point for the idea is the reported fundamental momentum — revenue up 16.0% quarter over quarter to $23.0B in Q2 2026, gross margin at a near-decade high of 85.8%, and operating cash flow roughly doubling to $10.7B — with Reuters reporting Lilly lifted its revenue outlook on weight-loss drug sales on Oct 29, 2026. The strongest point against is that the stock is not on sale: LLY closed at $1,366.63 on Oct 29, 2026, with 14-day RSI at 79.9 — well above the 70 overbought line — and about 13% above the entry zone near the $1,208.91 50-day EMA. Fundamentally, net margin did fall 6.5 points to 30.9%, debt-to-equity jumped from 1.39 to 1.62, and provisional filings for the period ended Sept 30, 2026 show about $2.9M of net open-market insider selling, so the growth is being financed expensively and insiders aren't buying the dip. The verdict flips if price pulls back roughly 11–13% into the $1,209–$1,232 zone with RSI recovering through 45, or if the next earnings report shows revenue stalling rather than margins recovering.

Trade now

**Wait.** The business case per the idea — Lilly's weight-loss franchise driving a raised revenue outlook while money rotates out of AI-pressured tech — is supported by the reported numbers: Q2 2026 (period ended June 30, 2026) revenue rose 16.0% quarter over quarter to $23.0B and operating cash flow roughly doubled to $10.7B. But today's entry conditions are nowhere near met. LLY last closed at $1,366.63 (as of Oct 29, 2026), about 13% above its 50-day EMA of $1,208.91 and 11% above the Bollinger midline of $1,232.41, and the 14-day RSI sits at 79.9 — deep in overbought territory, not recovering from a dip. Buying here means paying the highest price of the recent range, 61.8% above its range low, with no edge from the entry framework. The pivotal condition is a pullback to the EMA-50/Bollinger midline zone with an RSI recovery through 45; until that happens, this is a thesis to monitor, not a trade. The downside that matters: the thesis leans partly on a tech-led rotation that could reverse, and reported net margin already fell 6.5 points quarter over quarter to 30.9% on deal charges — the same "one-off" costs the idea dismisses. Scope note: this setup is not backtestable as supplied — historical performance could not be measured because LLY's raw and adjusted price series use different bases, and no robust parameter setup was established. The plan below rests on the rule definitions and live readings, not on demonstrated historical edge. ### Technical details Entry rule (EMA/BB/RSI Crossover Long, LLY daily): price at or below the 50-day EMA **and** at or below the Bollinger (20) middle band, with price above the 50-day EMA, and the RSI (14) crossing above 45. The RSI (14) is a momentum gauge from 0–100; readings above 70 signal an overbought market. Current state (observed Oct 29, 2026): - Price $1,366.63 vs. 50-day EMA $1,208.91 — condition **not met**; price is $157.72 above the trigger. - Price vs. Bollinger middle $1,232.41 — **not met**; $134.22 above. - RSI (14) at 79.9 vs. a cross above 45 — **not met**; roughly 35 points above the trigger, and also above the 70 exit threshold. - Exits as defined: RSI above 70 or a 60-bar holding limit (signal exit); price reaching the nearest resistance level ($1,249.45, currently below price); price crossing above the rank-2 support level ($1,163.79); fixed −2% stop and +4% take-profit. Sizing is fixed-risk at 2% with a 25% maximum position.

Demand Evidence Is Real, and the Cash Flow Numbers Back It

Takeaway: The company-level evidence — 16% sequential revenue growth, an 85.8% gross margin, and a doubling of operating cash flow — supports the idea that Lilly's demand momentum is genuine; the missing piece is that the proposed technical entry has no measured history behind it. ### ### ### Revenue acceleration confirms the demand thesis in the hard numbers The idea argues Lilly's raised outlook reflects durable weight-loss drug demand. The fundamentals agree: revenue rose from $19.8B in Q1 2026 to $23.0B in Q2 2026, a 16.0% sequential jump, and the latest full fiscal year showed 42.5% year-over-year revenue growth, in the 76th percentile of 1,042 Health Care peers. Reuters reported on 2026-10-29 that Lilly lifted its revenue outlook specifically on weight-loss drug sales. Growth of this magnitude at ~$90B annualized scale is not noise; it is the top-line signature of a franchise in mass adoption. ### Gross margin expansion undercuts the…

Scores

• Conviction score breakdown: 53
• Thesis support: 70
• Trade readiness: 15
• Risk quality: 52
• Fundamentals trend: 74

Watch items

• LLY — Close vs. 50-day EMA and Bollinger (20) midline
• LLY — RSI (14)
• LLY — Net margin, next reported quarter
• LLY — Insider net open-market activity